iShares Biotechnology ETF
289 hedge funds and large institutions have $4.49B invested in iShares Biotechnology ETF in 2014 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 90 increasing their positions, 97 reducing their positions, and 43 closing their positions.
44% more capital invested
Capital invested by funds: $3.12B → $4.49B (+$1.37B)
28% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 43
5% more funds holding in top 10
Funds holding in top 10: 19 → 20 (+1)
4% more funds holding
Funds holding: 278 → 289 (+11)
7% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 97
16% less call options, than puts
Call options by funds: $618M | Put options by funds: $736M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$228M |
| 2 |
Morgan Stanley
New York
|
+$222M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$198M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$175M |
| 5 |
Goldman Sachs
New York
|
+$165M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$58.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$35.8M |
| 4 |
SG Americas Securities
New York
|
-$19.3M |
| 5 |
MCM
Moore Capital Management
New York
|
-$18M |
IBB Hedge Fund Activity: Q1 2014 in Review
289 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2014, worth a combined $4.49B — up 44% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new IBB positions and 43 closed out — a net gain of 12 holders — while 90 added to existing stakes and 97 trimmed.
The largest buyer was Citigroup, adding an estimated $228M. The largest seller was Bank of Nova Scotia, cutting an estimated $58.3M.
- 289 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2014, up from 278 in Q4 2013.
- Funds reported $4.49B of iShares Biotechnology ETF stock for Q1 2014, up 44% quarter-over-quarter.
- 55 funds opened new iShares Biotechnology ETF positions in Q1 2014 and 43 closed out, a net change of +12 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2014 was Citigroup, an estimated $228M added.
- The largest iShares Biotechnology ETF seller in Q1 2014 was Bank of Nova Scotia, an estimated $58.3M sold.
Based on aggregated 13F filings for Q1 2014.